ConductScience.org, home

Paper19920100

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.

Mittendorf EA and 12 others. Clin Cancer Res, 2009. Cited by 286 papers, by iCite.

Cite this record

ConductScience Library. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Papers, record 19920100. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19920100

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
286
iCite
Relative citation ratio, by iCite
5.89
iCite
Revised in PubMed
2026-01-28
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mittendorf EAElizabeth A
2Wu YYun
3Scaltriti MMaurizio
4Meric-Bernstam FFunda
5Hunt KKKelly K
6Dawood SShaheenah
7Esteva FJFrancisco J
8Buzdar AUAman U
9Chen HHuiqin
10Eksambi SSameena
11Hortobagyi GNGabriel N
12Baselga JJose
13Gonzalez-Angulo AMAna M

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Breast NeoplasmsMajor topic
Neoadjuvant TherapyMajor topic
Erb-b2 Receptor Tyrosine KinasesMajor topic
Adult
Aged
Aged, 80 and over
Anthracyclines
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Cell Line, Tumor
Disease-Free Survival
Female
Humans
Middle Aged
Recurrence
Taxoids
Trastuzumab
Treatment Outcome

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K23 CA121994NCI NIH HHSUnited StatesK23CA121994PubMed and NIHNIH RePORTER
K99 CA133244NCI NIH HHSUnited StatesK99CA133244PubMed and NIHNIH RePORTER
1K99CA133244-01NCI NIH HHSUnited StatesK99CA133244PubMed and NIHNIH RePORTER
1K23CA121994-01NCI NIH HHSUnited StatesK23CA121994PubMed and NIHNIH RePORTER

Download CSV of grants

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116809727HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.J Clin Oncol2006https://conductscience.org/library/papers/16809727PubMed
219060928Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.Oncogene2009https://conductscience.org/library/papers/19060928PubMed
319596702Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.Ann Oncol2009https://conductscience.org/library/papers/19596702PubMed
49256133HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.J Clin Oncol1997https://conductscience.org/library/papers/9256133PubMed
52470152Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science1989https://conductscience.org/library/papers/2470152PubMed
616739334HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.Anticancer Res2006https://conductscience.org/library/papers/16739334PubMed
711916237Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.Clin Cancer Res2001https://conductscience.org/library/papers/11916237PubMed
87647336MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.Breast Cancer Res Treat1995https://conductscience.org/library/papers/7647336PubMed
912048273Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.J Natl Cancer Inst2002https://conductscience.org/library/papers/12048273PubMed
101967301Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.J Clin Oncol1990https://conductscience.org/library/papers/1967301PubMed
1117159189American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol2007https://conductscience.org/library/papers/17159189PubMed
1216236738Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med2005https://conductscience.org/library/papers/16236738PubMed
1310561337
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
J Clin Oncol1999https://conductscience.org/library/papers/10561337PubMed
1418757266Trastuzumab administration associated with change in HER2 status.Clin Breast Cancer2008https://conductscience.org/library/papers/18757266PubMed
1512506169Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.J Clin Oncol2003https://conductscience.org/library/papers/12506169PubMed
163798106Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987https://conductscience.org/library/papers/3798106PubMed
1710080586Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.J Clin Oncol1999https://conductscience.org/library/papers/10080586PubMed
1815738535
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
J Clin Oncol2005https://conductscience.org/library/papers/15738535PubMed
1916166438Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.Clin Cancer Res2005https://conductscience.org/library/papers/16166438PubMed
2016184453
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Breast Cancer Res Treat2005https://conductscience.org/library/papers/16184453PubMed

See all 28 referencesDownload CSV of references

Cited by172

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 286 citations.

PMIDTitleJournalYearIn PapersSource
42724786Residual disease in HER2-positive early breast cancer: are we escalating the RIGHT patients to T-DM1 or T-DXd?Transl Cancer Res2026https://conductscience.org/library/papers/42724786PubMed
42311837HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies.Breast Cancer (Dove Med Press)2026https://conductscience.org/library/papers/42311837PubMed
41899536Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/41899536PubMed
41642399Breast Cancer Brain Metastases: Current Understanding and Future Directions.Curr Oncol Rep2026https://conductscience.org/library/papers/41642399PubMed
41604118Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer.Int J Clin Oncol2026https://conductscience.org/library/papers/41604118PubMed
41462365Development and multicenter external validation of an intratumoral and peritumoral ultrasound-based radiomics model for preoperative prediction of HER2 status in IHC 2 + breast cancer.Eur J Med Res2025https://conductscience.org/library/papers/41462365PubMed
41402487Antibody-lectin chimeras for glyco-immune checkpoint blockade.Nat Biotechnol2026https://conductscience.org/library/papers/41402487PubMed
41155800The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study.Medicina (Kaunas)2025https://conductscience.org/library/papers/41155800PubMed
41113985Therapeutic challenges in HER2-targeted antibody therapies: trastuzumab and its ADC derivatives in breast cancer.Am J Cancer Res2025https://conductscience.org/library/papers/41113985PubMed
40930104Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.Cell Genom2025https://conductscience.org/library/papers/40930104PubMed
40910883Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms.Radiol Imaging Cancer2025https://conductscience.org/library/papers/40910883PubMed
40437301Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study.Breast Cancer Res Treat2025https://conductscience.org/library/papers/40437301PubMed
40265417Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody.Antibodies (Basel)2025https://conductscience.org/library/papers/40265417PubMed
40148195Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy.Breast2025https://conductscience.org/library/papers/40148195PubMed
40114960Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC).Transl Lung Cancer Res2025https://conductscience.org/library/papers/40114960PubMed
39786525Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing.Curr Oncol Rep2025https://conductscience.org/library/papers/39786525PubMed
39687980Breast biomarkers evolution between primary and distant metastasis: incidence and significance.Histopathology2025https://conductscience.org/library/papers/39687980PubMed
39473863Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature.World J Clin Oncol2024https://conductscience.org/library/papers/39473863PubMed
39468041Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.NPJ Breast Cancer2024https://conductscience.org/library/papers/39468041PubMed
39350043Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study.BMC Cancer2024https://conductscience.org/library/papers/39350043PubMed

See all 172 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19920100

GET https://conductscience.org/api/papers/v1/19920100/references?page=2